Ionetix Corp / DE /
CIK 2108121fmd_035Y6473RMQ0Q1KMCC84V7N1PYManufacturing · In Vitro & In Vivo Diagnostic SubstancesTemplate: Standard
Coverage: Jan 01, 2025 to Sep 30, 2026, 6 periods
Latest quarter · Q3 FY2026
Millions- Total revenues
- 1
- Gross profit
- 0
- Operating income
- (5)
- Net income
- (5)
- Free cash flow
- (5)